Abstract 1431P
Background
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) is emerging as a promising strategy for treating patients with esophageal cancer. We aimed to develop a novel, voxel-level radiomics deep learning model to predict the pathological complete response (pCR) to nCIT in esophageal squamous cell carcinoma (ESCC).
Methods
We included 745 ESCC patients from three institutions, comprising a training set (N=500, institution 1), test-set-1 (N=86, institution 1), test-set-2 (N=34, institution 2), and test-set-3 (N=125, institution 3). All patients underwent nCIT and received a pathological evaluation post-surgery. A total of 104 distinct radiomic features were extracted from the tumor areas in CT images prior to nCIT. Features demonstrating predictive power with an area under the receiver operating characteristic curve (AUROC) exceeding 0.6 were retained. Each selected radiomics feature map, along with the original image, was input into a vision transformer model as a separate channel. The Shapley Additive exPlanations method was employed to visualize feature importance and identify predictive regions within the tumor, enhancing the model’s interpretability. For baseline comparison, we also constructed a clinical model using only clinical factors, and compared it against traditional radiomics and ResNet models.
Results
The voxel-level radiomics deep learning model achieved an AUC of 0.825 with an accuracy of 76.2% in test-set-1, 0.751 and 68.5% in test-set-2, and 0.819 with 78.1% in test-set-3, respectively. It demonstrated superior predictive performance compared to the clinical model, traditional radiomics model, and ResNet model.
Conclusions
This innovative and noninvasive voxel-level radiomics deep learning approach offers an efficient and accurate approach of predicting treatment response to nCIT in ESCC, potentially benefiting clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
951P - CA19-9-related macrophage polarization has prognostic value in patients with HCC after immune checkpoint inhibitor treatment
Presenter: Meiyan Zhu
Session: Poster session 17
952P - Comprehensive analysis of cytokines and PDL1 before and after administration of atezolizumab and bevasizumab in patients with HCC
Presenter: Kyoji Ito
Session: Poster session 17
953P - Vessels that encapsulate tumor clusters (VETC): A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations
Presenter: Yanjiang Yin
Session: Poster session 17
954P - Evaluation of antigen-specific CD8 T cell responses to predict efficacy of atezolizumab and bevacizumab treatment in hepatocellular carcinoma
Presenter: Angélique Vienot
Session: Poster session 17
957P - Modelling immune-mediated cytotoxicity for HCC with patient-derived organoid co-culture platform
Presenter: Tsz Tung Kwong
Session: Poster session 17
958P - Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection
Presenter: Xinrong Yang
Session: Poster session 17
959P - Machine learning-based MRI radiomics predicts overall survival of unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus PD-(L)1 inhibitors and molecular targeted therapy
Presenter: Bin-Yan Zhong
Session: Poster session 17
960P - Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening
Presenter: Hee-Jung Wang
Session: Poster session 17